RNS Number : 8260X
Pharma C Investments PLC
22 December 2023

22 December 2023

Pharma C Investments PLC

("Pharma C" or the "Company")

Restoration to Trading, Issue of Equity, Proposed Board Changes and PDMR

Pharma C (AQSE: PCIL) is pleased to announce that, following the publication of the Interim results, trading in the Ordinary Shares of the Company will resume at 8am on Wednesday, 27 December 2023.

Issue of Equity
As per the Notice of General Meeting dated 24 November 2023, the Company had conditionally raised £281,000 by way of the Subscription of 2,810,000,000 subscription shares ("Subscription Shares") at the price of £0.0001 ("Issue Price"). The Subscription was conditional upon the passing of the resolutions at the General Meeting and admission of the Subscription Shares to trading on AQSE. Following the resolutions being passed at the General Meeting held on 11 December 2023 and the restoration to trading on AQSE, a total of 2,810,000,000 Subscription Shares will be issued. In addition, the Company has agreed to settle further outstanding debt by issuing 25,000,000 Subscription Shares at the Issue Price. The Subscription Shares will represent a total of 91.31% of the enlarged share capital.

Application will be made for the Subscription Shares, which will rank pari passu with the existing Ordinary Shares in issue, to be admitted to trading on the AQSE Growth Market ("Admission"). Dealings are expected to commence on or around 2 January 2024.

Total Voting Rights
Following Admission, the Company's total issued and voting share capital will consist of 3,104,857,144 Ordinary Shares. The Company does not hold any ordinary shares in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules

Board Changes
The Company is also today announcing the following Board appointments which will be made once First Sentinel Corporate Finance has conducted the necessary checks as required by the AQSE Rules. A further announcement will be made upon the appointments being made:
- Peter Wall joins as Executive Chairman;
- Philipp Kallerhoff and Sarah Gow join as Non-Executive Directors;
- Gavin Sathianathan steps down from the board as Investment Strategy Director once the above appointments become effective;
- Jeremy Woodgate remains on the Board as Independent Non-Executive Director.

Peter Wall is an active leader in the technology sector, best known for his tenure as CEO and Chairman of Argo Blockchain, a company he guided to a successful NASDAQ listing in 2021. Under his leadership, Argo raised over $200 million in capital, solidifying its status as a key player in the blockchain industry. Peter was the driving force behind Argo's growth, starting with assembling its initial team and establishing the first facility in Gatineau, Quebec, to orchestrating expansive operations and adopting innovative technologies that enhanced efficiency and minimized environmental impact.

In addition to his achievements at Argo, Peter served as Chairman of LSE-listed Cellular Goods. His ability to navigate complex technological landscapes has also led to significant contributions across various other industries, including co-working, journalism, and communications.

Philipp Kallerhoff is an accomplished leader in the fields of technology and finance. As the founder of Protos Management, Philipp has been at the forefront of digital asset investment, demonstrating his deep understanding of the blockchain industry. His tenure as Director at Harcourt/Vontobel Asset Management AG in Zurich emphasized his proficiency in applying machine learning to market dynamics. Philipp's entrepreneurial journey includes co-founding Jumiya Inc., which transformed financial data analysis through big data analytics.

An alumnus of Singularity University with a Doctorate in Computational Neuroscience and multiple degrees from TU Berlin, Philipp skillfully blends academic rigor with entrepreneurial zeal. His educational background in engineering, management, psychology, and physics underlines his multidisciplinary approach to problem-solving and innovation.

Sarah Gow brings over 19 years of banking industry expertise, with significant roles at Citigroup Asset Management, where she served as Director of Global Operations in New York and Head of Operations in London. Sarah's strategic vision and operational leadership were also evident during her tenure at HSBC Global Asset Management as a Project Manager. As a founding partner of UK-based TrinityCapM Ltd, she demonstrated her entrepreneurial acumen in asset management. Notably, Sarah contributed her governance and oversight skills to the board of Argo Blockchain, playing a key role during its milestone NASDAQ listing in 2021.

Information for the purpose of Rule 4.9 of the AQSE Growth Market Access Rulebook for the new directors will be provided once the board appointments have been made.

The Directors of Pharma C take responsibility for this announcement.

For further information please visit www.pharmacinvestments.com

Pharma C Investments	
Gavin Sathianathan	Via First Sentinel
First Sentinel Corporate Finance	
Brian Stockbridge, Corporate Adviser	+44 20 3855 5551

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	**Details of the person discharging managerial responsibilities / person closely associated**	
a)	Name	Jeremy Woodgate
2.	**Reason for the Notification**	
a)	Position/status	Independent Non-Executive Director
b)	Initial notification / Amendment	Initial notification
3.	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Pharma C Investments PLC
b)	LEI	213800CBZ6E6WRDGV387
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument Identification Code	Ordinary shares GB00BJDPYD55
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Price(s): £0.0001 per Ordinary Share Volume(s): 25,000,000 Ordinary Shares
d)	Aggregated information: · Aggregated volume · Price	25,000,000 Ordinary Shares £2,500

e)	Date of the transaction	27 December 2023
f)	Place of the Transaction	Aquis Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXDZMZZZZDGFZM